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A Comparison of Clonidine, Clonidine/Naltrexone, and 
Buprenorphine in Primary Care-Based Outpatient Opiate 
Detoxification 
Edward Paul Weiss 
1992 
Detoxification from opiate abuse can be effectively carried out in a 
primary care setting utilizing clonidine (an alpha-2 agonist) and 
clonidine/naltrexone (clonidine combined with an opiate antagonist), as 
demonstrated by open trials of these two methods. The present study is the 
first randomized trial carried out in a primary care clinic that was designed to 
directly compare three methods of opiate detoxification: clonidine, 
clonidine/naltrexone, and buprenorphine (a partial opioid agonist). 
The combined success rate of these methods was 70% (68/97). 
Individually, the clonidine (C) detoxification protocol had a success rate of 
48% (15/31), the clonidine/naltrexone (C/N) protocol had a success rate of 
82% (27/33), and the buprenorphine (B) protocol had a success rate of 79% 
(26/33). The clonidine/naltrexone and buprenorphine protocols had 
significantly higher success rates than the clonidine protocol (p<0.01). The 
buprenorphine group had a significantly lower mean peak symptom severity 
score (maximum=72) than the clonidine/naltrexone group by day 3 of 
detoxification (C/N=25.8; B=12.6; p<0.005). The value of this score on day 3 
for the clonidine group was also in the mild range (18.0). Of the 68 patients 

who were successfully detoxified, 51 (75%) were successfully referred to a 
naltrexone maintenance relapse prevention program. There were no 
serious medical complications resulting from any of the treatment protocols. 
The conclusions of this study are that the use of either 
clonidine/naltrexone or buprenorphine is more effective than the use of 
clonidine alone in achieving opiate detoxification, that detoxification with 
buprenorphine reduces withdrawal symptoms to a greater degree than does 
clonidine/naltrexone, and that each of the three methods of opiate 
detoxification evaluated are safe and appropriate for use in a primary care- 




Opioid Addiction and the Opioid Receptors: The complex 
problem of opiate use in our society has a significant impact on our medical, 
financial, and criminal justice systems. The chronic use of opiate drugs sets 
up a cycle of direct effects, tolerance, dependence, and withdrawal. Once 
initiated, this cycle is self-perpetuating and difficult to break. The basic 
principles of human opiate addiction are, in part, a reflection of the intricate 
pharmacology and physiology of the opiates. 
The fear and pain associated with opiate withdrawal is the catalyst for 
the perpetuation of the cycle of opiate use. Insomnia, tremor, muscle pain, 
restlessness and anxiety are only a few of the disturbing symptoms of the 
well-characterized opiate withdrawal syndrome (Kolb and Himmelsbach, 
1938). The opiates are able to produce their varied effects through 
competitive interaction with pharmacologically differentiable populations of 
opiate receptors that are present in diverse areas of the brain and body 
(Martin, 1967). Martin classified these receptors into three functionally 
discreet types which he called mu, kappa, and sigma (Martin et al., 1976). 
The subsequent discovery of the enkephalins and the endorphins (Hughes 
et al., 1975; Cox et al., 1977), which are both endogenous proteins with 
opioid activity in the brain, raised the possibility that the heterogeneity of the 
opioid receptor exists at a physiologic level, investigation into this receptor 
heterogeneity led to the proposal of the existence of yet fourth and fifth types 
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of opioid receptors, which were called delta and epsilon (Lord et al., 1977; 
Schulz et al., 1980). The clinical importance of this work on the opiate 
receptor is the theoretic possibility of separating out the effects of the various 
opiate agonists in terms of their interaction at these different receptors. 
However, to date it has not been possible to separate out some of the 
opiates' desirable effects, such as analgesia, from their undesirable effects, 
such as the production of dependence and tolerance, based on selective 
interaction at the various receptors. In fact, most mu and delta agonists have 
effects at both of these receptors, and the pharmacologic effects of mu and 
delta agonists are not easily distinguished (Shearman and Herz, 1982 a,b). 
The mu receptor is the "classic" opiate receptor, and morphine is its 
prototypic agonist. Heroin, which is a commonly used illicit cousin of 
morphine, is also a potent mu agonist. Historically, the intravenous use of 
morphine in this country generally began during the American Civil War 
period, at which time the hypodermic syringe was introduced. A shift to 
heroin occurred in the late 1800's. During that period, in an attempt to 
control opiate use by immigrant Chinese laborers, the U.S. Government 
passed the first laws that made opiate use illegal. A consequence of this 
action was that opiate use and distribution became attractive to organized 
crime. The illegal popularity of heroin increased throughout the 1920‘s, as 
further laws were passed which prohibited most physicians from 
prescribing opiates at the time (Platt and Labate, 1976). 
The effects of a mu agonist include miosis, bradycardia, hypothermia, 
analgesia, sedation, and decreased vigilance (Redmond and Krystal, 
1984). In a chronic mu agonist user, the abrupt discontinuation of the 
agent or the administration of a mu antagonist such as naloxone, produces 
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the classic opiate withdrawal syndrome (Herz et al., 1982). There has 
been extensive investigation into the changes that occur in multiple 
intracellular messengers and neurotransmitter systems during chronic use 
of opiates and during their withdrawal. Changes in intracellular cAMP and 
calcium concentrations during the phases of acute opioid administration, 
opioid tolerance, and withdrawal have been documented (Collier et al., 
1972; Guerriro-Munoz et al., 1979). The role of the endogenous opioids in 
the scheme of exogenous opiate dependence and withdrawal has also 
been investigated. It appears that there is no change in brain enkephalin 
after chronic morphine administration (Childers et al., 1977; Shani et al., 
1979), although Przelocki et al. (1979) report a decrease in endorphin 
synthesis in rat brain under such conditions. No definite conclusions can 
be drawn from the present information regarding endogenous opioids, and 
their degree of participation in opiate dependence and withdrawal remains 
an open question. 
Interaction of the Opioid and Noradrenergic Systems: The 
neurotransmitter system that has been best characterized as having a direct 
association with the opiate withdrawal syndrome is the noradrenergic 
system centered in the locus coeruleus (LC). The LC receives input from the 
primary pain and sensory systems, and sends efferent signals to many 
regions of the brain that are associated with specific physiological changes 
seen in the opiate withdrawal syndrome. It is interesting that direct 
stimulation of the LC produces several behavioral and physiological signs of 
the opiate withdrawal syndrome in monkeys (Redmond, 1981). The release 
of norepinephrine from LC efferents is inhibited by activation of presynaptic 
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alpha-adrenergic receptors (Cedarbaum and Aghajanian, 1977). The 
discovery of a high concentration of receptors for endogenous opioids in the 
LC (Pert et al., 1975) prompted further investigation into the possible 
interactions between the opioid and noradrenergic systems. It was found 
that systemically administered opioids acutely inhibit neuronal firing rates in 
the LC (Korf et al., 1974), and that chronic opioid administration results in 
tolerance to this inhibitory effect. Moreover, abrupt withdrawal of opioid in a 
dependent rat results in hyperactivity of the LC (Aghajanian, 1978) as well 
as elevated brain and plasma levels of the norepinephrine metabolite 3- 
methoxy-4-hydroxyphenelethylene glycol (MHPG) (Crawley et al., 1979). 
Chronic administration of opioids also induces an increase in the number of 
post-synaptic alpha and beta adrenergic receptors, which in effect results in 
a post-synaptic adrenergic supersensitivity (Hamburg and Tallman, 1981). 
The concept of the opiate withdrawal syndrome being mediated by 
hyperactivity of the central noradrenergic system is further supported by 
evidence that the drug clonidine, a specific alpha-2 agonist, is able to 
suppress biochemical and clinical signs of the syndrome. 
Aghajanian (1978) found that naloxone-precipitated withdrawal from 
opiates in the rat brain produced noradrenergic hyperactivity, as reflected in 
a measured increase in the firing rate of noradrenergic neurons in the LC, 
and that this increase in firing rate was reversed by the iontophoresis of 
clonidine onto the cell bodies of the LC. Furthermore, when naloxone was 
applied, it could block morphine's suppression of the LC firing rate, while at 
the same time clonidine was still able to induce suppression. Also, when 
piperoxane (a specific alpha-2 antagonist) was applied, it could block 
clonidine's suppression of the firing rate, but could not block morphine’s 
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ability to acutely suppress the firing rate. Aghajanian therefore concluded 
that there existed two separate receptor systems in the LC, the opiate 
receptor and the alpha-2 adrenergic receptor, which could interactively 
modulate the firing of the LC during opiate administration and withdrawal. 
While there is substantial evidence to implicate the LC's role in opiate 
withdrawal as discussed above, it is not clear that the LC is the only region 
of the brain involved. Both opiate and alpha-2 adrenergic receptors are 
found in other regions of the nervous system such as the amygdala, 
forebrain, and spinal cord. Several investigators have suggested that there 
is significant action of clonidine both pre-synaptically and post-synaptically 
in these regions during opiate withdrawal (Freedman and Aghajanian, 1985; 
Franz, et al., 1982; Matsui and Yamamoto, 1984). 
The elevated brain and plasma levels of MHPG observed during opioid 
withdrawal in rats are suppressed by administration of clonidine (Crawley et 
al., 1979), paralleling the decrease in LC firing rate. There is biochemical 
evidence that there are elevated norepinephrine metabolite levels during 
opioid withdrawal in humans as well. Charney et al. (1984), in a double¬ 
blind, placebo controlled study, found a significant elevation of serum MHPG 
levels in methadone-maintained patients who underwent naltrexone- 
precipitated withdrawal. In that study there was also a significant correlation 
of the elevated MHPG levels during withdrawal to the severity of rated signs 
and symptoms of withdrawal. 
Clinical Use of Clonidine: The association between the opioid 
and noradrenergic systems extends beyond the biochemical and cellular 
levels, and can be applied directly to the clinical management of humans 
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undergoing withdrawal from opiates. Preliminary results of clonidine's 
efficacy in alleviating the signs and symptoms of opiate withdrawal in 
humans was published by Gold et al. (1978a). They found that clonidine 
rapidly and dramatically alleviated withdrawal signs when given to patients 
in the midst of methadone withdrawal. The first double-blind, placebo 
controlled clinical trial of clonidine in opiate detoxification was carried out by 
Gold et al. (1978b) in an inpatient setting. The subjects were on 
maintenance doses of methadone (15-50 mg./day). Clonidine (5 
micrograms/kg.) was given thirty-six hours after the last methadone dose, at 
a point where all eleven of the subjects were experiencing withdrawal 
symptoms. All of the subjects subsequently had their withdrawal signs 
nearly eliminated for 4 to 6 hours following the clonidine dose. Subsequent 
inpatient studies have supported Gold's success in demonstrating that 
clonidine can significantly decrease the signs and symptoms of opiate 
withdrawal in patients withdrawing from methadone. Success rates ranging 
from 80% to 100% have been reported (Uhde et al., 1980; Kieber et al., 
1980; Charney et al., 1981). 
Outpatient trials of clonidine in opiate withdrawal have reported varying 
degrees of success. In an open trial using individually adjusted doses of 
clonidine, Washton and Resnick (1980a) reported a success rate of 80% in 
detoxifying patients from methadone maintenance, and a success rate of 
36% in detoxifying patients from heroin. Success was defined as the 
number of patients who remained opiate-free during the ten day course of 
clonidine. In a subsequent double-blind study by the same investigators 
(Washton and Resnick, 1980b) that compared the efficacy of clonidine to that 
of a rapid methadone taper in outpatient detoxification of methadone 
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maintained patients, a success rate of 31% (4/13) for the clonidine group 
was achieved, while a success rate of 46% (6/13) for the methadone taper 
was reported. There was no significant difference between the success 
rates reported in that study. 
A similar comparison was made by Kleber et al. (1985), who studied 
patients maintained on 20 mg. of methadone per day. Patients in the 
clonidine group were abruptly switched from methadone to clonidine plus 
placebo methadone. Patients in the methadone taper group received a 
decremental decrease in their methadone dose by 1 mg./day, and received 
placebo clonidine. The investigators found that 42% of the patients who 
were administered clonidine achieved successful detoxification, while 39% 
of the patients who received a rapid methadone taper achieved successful 
detoxification. Again, there was no significant difference between these 
success rates. The authors observed that al! of the treatment failures in the 
clonidine group occurred during the first two weeks of the four week course. 
This was the period during which those patients reported the most 
withdrawal symptoms as well as symptoms attributed to clonidine, which 
most commonly included dizziness and lethargy. The treatment failures in 
the methadone taper group were mostly during the second two weeks of the 
study, at which time the methadone doses were below 10 mg./day. It was 
also observed that patients in the clonidine group who remained in the study 
through the first two weeks were all able to go on to complete the 
detoxification successfully. 
Clinical Use of Naltrexone: The lower success rates obtained for 
outpatient opiate detoxification with clonidine when compared to the 
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markedly high success rates for inpatient trials could be secondary to the 
availability of illicit opiates in an outpatient setting. The outpatient trials all 
lasted at least ten days, during which the patients were symptomatic from 
opiate withdrawal. Along with the physiologic changes described during the 
opiate withdrawal syndrome, there are psychological disturbances such as 
anxiety and drug craving. An effort was therefore made to devise a 
detoxification scheme that would not only diminish the symptoms of opiate 
withdrawal but would also significantly shorten the duration of the 
withdrawal syndrome. 
The pharmacologic agent invoked to speed the process of opiate 
withdrawal is an opiate antagonist such as naloxone (N- 
aliylnoroxymorphone). Naloxone is a competitive inhibitor of the opiate 
agonists at the mu receptor, and is able to displace opioids from this 
receptor and prevent further opioid binding (Eddy and May, 1973). 
However, naloxone is only effective when administered parenterally, and 
can only maintain opiate blockade for less than 1-2 hours, which is shorter 
than the effective half life of morphine and methadone. Naltrexone (N- 
cyclopropyl-methylnoroxymorphone), a long acting, orally effective analogue 
of naloxone was therefore developed (Blumberg and Dayton, 1972). 
Blachley et al. (1975) used repeated doses of naloxone to successfully 
precipitate and shorten the withdrawal period to 1 or 2 days in opioid- 
dependent persons. The overall severity of the individual withdrawal 
symptoms elicited were not different from those experienced during an 
opiate detoxification that follows its natural course. Other investigators were 
also able to demonstrate naloxone's ability to shorten the withdrawal period 
(Kurland and McCabe, 1976; Resnick et al., 1977). However, the 
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compression of five-day's worth of withdrawal symptoms into 1 or 2 days 
was not acceptable by most of the patients, who complained of increased 
intensity of withdrawal symptoms directly following naloxone administration. 
Clinical Use of Clonidine/Naltrexone: In 1980 Riordan and 
Kleber combined the useful properties of both naloxone and clonidine to 
achieve opiate detoxification that was abrupt, but well tolerated by the 
patients. They studied four subjects, three heroin users and one methadone 
user, who were admitted for four days to an inpatient ward for the 
detoxification procedure. The patients were pre-treated with clonidine 
during the first day and their opiates were withheld. Naloxone was 
administered on days two and three, requiring intramuscular injections every 
two hours for a total of six doses per day, and clonidine dosing was 
continued. By the fourth day, none of the patients reported symptoms in 
response to a naloxone challenge, and the authors concluded that the 
patients could then immediately start long term opiate blockade with daily 
naltrexone. The patients tolerated this procedure well, with symptom 
severity scores highest (range 5-9 out of possible 22) on the second 
treatment day. This study was successful in demonstrating that clonidine 
can ameliorate the withdrawal symptoms precipitated by naloxone in opioid- 
dependent humans, and that this combination of drugs was effective in 
achieving rapid opiate detoxification. 
The effectiveness of using naltrexone rather than naloxone in 
conjunction with clonidine in an inpatient setting was evaluated by Charney 
et al. (1986). In a double-blind, placebo controlled study forty methadone 
addicted persons (using 10-65 mg. of methadone per day) were detoxified 

using clonidine plus naltrexone. The patients received their maintenance 
dose of methadone on day one, and on day two the methadone was 
withheld and clonidine was administered. Then on day three, naltrexone 
was given orally every four hours, and clonidine dosing was continued. 
Over a course of seven days total, the naltrexone dose was increased while 
the clonidine dose was tapered. At the end of the seven day protocol, 95% 
(38/40) of the patients were successfully detoxified, and were on a blocking 
dose (50 mg./day) of naltrexone. The severity of withdrawal signs and 
symptoms was greatest on days 3 and 4 (the first two days of naltrexone 
therapy), and decreased rapidly afterward. The severity of these signs and 
symptoms did not appear to be related to the patients' methadone dose or 
duration of use. The authors note that while clonidine was able to 
significantly suppress the signs and symptoms of withdrawal, it was not able 
to completely eliminate them. Clinically significant decreases in systolic and 
diastolic blood pressures were noted on clonidine days 1, 2 and 3, however 
no syncopal episodes were reported, and patients experienced only mild 
postural lightheadedness. Other commonly reported side effects of 
clonidine were sedation, constipation, and dry mouth. 
The success of the above inpatient trial of combined clonidine and 
naltrexone detoxification of methadone addicts led Kleber et al. (1987) to 
conduct an open trial of this combination for detoxification of heroin addicts 
in an outpatient setting. Fourteen heroin-addicted persons were studied in a 
five day detoxification protocol. The severity of each patient's addiction was 
quantified using a naloxone challenge test (NCT) on day one. Then on day 
two each patient received a dose of clonidine and naltrexone in accordance 
with their score on the NCT, and over the course of five days the naltrexone 

dose was gradually increased while the clonidine dose was gradually 
decreased. Twelve of the 14 patients (86%) were successfully detoxified 
and on a blocking dose of naltrexone by day 5. At one month follow-up, 5 of 
the 12 patients remained in a naltrexone maintenance program, and another 
3 remained drug free. The patients experienced withdrawal symptoms on 
day 1 (after the NCT) and day 2, and these were significantly diminished by 
clonidine. Once the patients' cumulative dose of naltrexone exceeded 8 to 
10 mg., no withdrawal symptoms were elicited by further naltrexone doses. 
There was a significant correlation between the patient's NCT score and the 
mean number of withdrawal symptoms reported. Clonidine was noted to 
significantly lower blood pressures, but no syncopal episodes were 
reported, and no rebound hypertension was observed upon clonidine taper 
at the end of the protocol. The authors (Kleber et al., 1987) concluded that 
this protocol of combined clonidine and naltrexone treatment was more 
effective than previously reported trials with clonidine alone (see above, 
Washton and Resnick, 1980a). Also, the success rate achieved with 
clonidine plus naltrexone in detoxifying heroin-addicted persons was 
comparable to that of earlier studies using methadone-addicted persons 
(Charney et al., 1986). Furthermore, the authors suggest that the 
clonidine/naltrexone protocol equalizes the time course of the heroin and 
methadone withdrawal syndromes. This may be accomplished by 
naltrexone's displacement of opioids from binding sites, resulting in 
elimination of the effect of the opioid's half-life on the time course of the 
withdrawal syndrome . 
In a study designed to develop a daily naltrexone dosing schedule with 
doses that are easily available commercially, Vining et al. (1988) studied 17 

heroin-addicted persons in a four or five day outpatient detoxification 
protocol utilizing clonidine plus naltrexone. They found that 14 of the 17 
(82%) were able to successfully complete the protocol, with a minimal 
amount of withdrawal signs and symptoms observed (also Vining, 1987). 
The use of clonidine and clonidine plus naltrexone to achieve 
outpatient opiate detoxification in a primary care setting was assessed in an 
open trial by O'Connor et al. (in press). The authors report an overall 
success rate of 61% (38/62), with 43% (17/40) of patients in the clonidine 
group and 95% (21/22) of patients in the clonidine plus naltrexone group 
successfully completing the detoxification course. One month follow-up 
revealed that overall, 78% (35/45) of the patients who were successfully 
detoxified remained in a relapse prevention program. The authors conclude 
that clonidine plus naltrexone is more effective in achieving initial opiate 
detoxification than clonidine alone, but that both are suitable for use in a 
primary care setting. 
The Pharmacology of Buprenorphine: While the success rates of 
outpatient clonidine/naltrexone detoxification protocols are impressive, this 
does not obviate the need to investigate other potentially effective means to 
achieve the goal of opiate detoxification. Buprenorphine, a highly lipophilic 
oripavine derivative, is classified as a partial agonist of the mu opiate 
receptor (Martin et al., 1976). Buprenorphine has undergone extensive 
clinical evaluation as an analgesic agent. It was initially studied for use in 
control of post-operative and intractable pain (Houde, 1979; Kay, 1978). 
Buprenorphine has also been evaluated for use in analgesic anaesthesia, 
and has been found to be as effective as fentanyl in suppressing tachycardia 

and increased arterial pressure in response to major abdominal surgery 
when used in conjunction with nitrous oxide (Kay, 1980). More recently, 
buprenorphine has been investigated as an agent for the treatment of 
cocaine abuse (Kosten et al., 1989). Buprenorphine's complex 
pharmacologic properties make it a potentially useful agent for opiate 
detoxification as well. 
As a partial opiate agonist, buprenorphine has actions that are similar 
to both morphine and naloxone. In several antinociceptive assays in 
rodents, buprenorphine was shown to be 25-40 times more potent in 
analgesic ability than morphine, and equally potent as naloxone as a 
morphine antagonist. Buprenorphine was also shown to have a longer 
duration of analgesic action than morphine (Cowan et al., 1977). In 
experiments with chronic spinal dogs (dogs whose spinal cords were 
transected at the T10 level in order to assay the effects of opiate 
administration and withdrawal on autonomic and spinal cord mediated 
responses), Martin described buprenorphine as being 100 times more 
potent than morphine in suppressing a flexor reflex in response to pain 
(Martin, 1979). Martin's experiments further characterized the morphine-like 
properties of buprenorphine: he found that buprenorphine was able to 
suppress withdrawal symptoms in morphine-dependent dogs; after chronic 
administration of buprenorphine a mild withdrawal syndrome was observed 
upon discontinuation of buprenorphine; naloxone precipitated a mild 
.withdrawal syndrome in buprenorphine-dependent dogs, but was 1/30 as 
potent in precipitating withdrawal signs as it was in precipitating withdrawal 
in morphine-dependent dogs. Martin also defined buprenorphine's 
naloxone-like properties: buprenorphine precipitated withdrawal in 

morphine-dependent dogs, and was equivalent to naltrexone in its duration 
of action as an opiate antagonist. 
A significant aspect of buprenorphine's analgesic and antagonistic 
effects is the shape of the dose-response curve obtained when these 
parameters are studied. Martin (1979) described a ceiling effect for 
buprenorphine's analgesic ability. Also, the slope of the dose-response 
curve for buprenorphine's ability to suppress withdrawal signs in morphine- 
dependent dogs was less than that for morphine itself. Furthermore, the 
dose-response curve obtained during studies of buprenorphine's ability to 
precipitate withdrawal also revealed a lesser slope than that of the pure 
antagonist naloxone. This difference in the dose-response curve for 
analgesic ability between morphine and buprenorphine was supported by 
studies in mice and rats. In antinociceptive assays, a biphasic or “bell- 
shaped" dose response curve was obtained for buprenorphine, with the 
antinociceptive effect decreasing at higher doses. This was in comparison 
to the typical sigmoid shaped curve obtained for morphine (Cowan and 
MacFarlane, 1977). 
These differences in dose-response relationships between 
buprenorphine and the pure agonist morphine and pure antagonist 
naloxone led Martin to classify buprenorphine as a partial agonist at the mu 
receptor, with higher affinity but less intrinsic activity than morphine. 
Subsequent investigations have shown that buprenorphine possesses 
antagonistic ability at the kappa opioid receptor as well (Negus et al., 1989; 
Negus and Dykstra, 1988). 
The molecular pharmacology that is responsible for buprenorphine's 
partial agonist activity has been worked out by Ranee (1979). Ranee 
. 
attributes buprenorphine's properties to two separate mechanisms. One of 
these mechanisms is called non-competitive auto-inhibition. This 
phenomenon was first described by Ariens et al. (1964), and applied to 
buprenorphine's biphasic analgesic action by Ranee. Non-competitive auto¬ 
inhibition describes a situation in which a compound can interact with a first 
receptor to produce an effect, as well as interact at a second receptor at 
which the effect induced at the first receptor is antagonized. As applied to 
buprenorphine, Ranee proposes that buprenorphine has affinity not only for 
the mu receptor, but also for a second interdependent receptor, and as a 
result of increasing interaction between buprenorphine and the second 
receptor, the intrinsic activity of the buprenorphine-mu complex decreases. 
A second mechanism was described by Ranee that can account for the 
lesser slope of buprenorphine's dose-response curves for analgesic and 
antagonistic ability, and also account for buprenorphine's longer duration of 
action and the minimal withdrawal symptoms observed upon abrupt 
discontinuation of buprenorphine in buprenorphine-dependent animals. 
This mechanism is the relatively slow kinetics of the buprenorphine-opiate 
receptor interaction (Ranee, 1979; Hambrook and Ranee 1976). These 
investigators found that buprenorphine dissociated extremely slowly from 
the mu receptor when compared to morphine and naloxone, and that the 
rate of dissociation was independent of the nature of the competing drug. 
These slow buprenorphine-receptor kinetics can explain the minimal 
withdrawal symptoms seen upon buprenorphine withdrawal in tests of direct 
dependence. Homeostatic mechanisms are given time to control 
biochemical imbalances which result from abrupt withdrawal of the drug and 
which would otherwise be responsible for the excitatory withdrawal 

syndrome (Ranee 1979). The slow buprenorphine-receptor kinetics can 
also explain the difficulty observed in reversing buprenorphine's analgesic 
effect with naloxone. It is probable that the equilibrium distribution of the mu 
receptor between buprenorphine and naloxone is so slowly reached, that 
the short-lived naloxone is cleared from the central nervous system before 
significant displacement of buprenorphine can occur (Hambrook and Ranee 
1976). 
The Human Pharmacology of Buprenorphine: The human 
pharmacology of buprenorphine was extensively investigated by Jasinski et 
al. (1978), who used healthy male federal prison volunteers as study 
subjects. To assess the potency of buprenorphine in comparison to 
morphine and methadone with respect to physiologic and subjective effects, 
single-dose studies were carried out in a double-blind fashion with placebo 
controls. A total of 39 subjects underwent the single-dose studies that 
utilized a buprenorphine dose range of 0.2 mg. to 2.0 mg. s.c., morphine 
doses of 15 to 30 mg. s.c., and a methadone dose of 30 mg. s.c.. Results 
from these studies indicated that buprenorphine was 25 to 50 times more 
potent than morphine, with a concordance of potency estimates across all 
measures: change in pupil size, opiate-like symptom scale, opiate-like signs 
scale, subject's "liking" scale, "euphoria" scale, observer "liking" scale. 
There was a trend for buprenorphine to be less potent relative to morphine 
as the doses of both were increased, but no ceiling effect was noted in the 
dose range studied. Buprenorphine produced peak miosis 2 to 3 hours later 
than did morphine or methadone. Other studies examining buprenorphine's 
pupillary effects as an indicator of physiologic effect in humans have 

supported Jasinski's observations (Pickworth et al., 1991; Pickworth et al., 
1990). 
To determine if buprenorphine would produce morphine-like effects 
and to learn if physical dependence developed, five subjects underwent 
direct addiction studies during which they received 8 mg. of buprenorphine 
per day (Jasinski et al., 1978). During this chronic administration phase, the 
subjects reported a degree of "liking" similar to that reported by patients 
receiving morphine, and also reported similar complaints of constipation and 
difficulty with urination. Buprenorphine also produced miosis, and 
decreased diastolic and systolic blood pressures. Throughout the course of 
chronic administration, there was no evidence of laboratory values that 
exceeded clinically normal values. To determine if physical dependence 
had developed in these 5 subjects, naloxone was administered in a double¬ 
blind fashion on days 45 to 52. It was found that a large dose (4 mg.) of 
naloxone did not precipitate withdrawal in the subjects. Buprenorphine 
administration was then abruptly changed to placebo, and the subjects 
experienced a mild and delayed withdrawal syndrome: pupils dilated to pre¬ 
drug control diameters after 8 days, pulse rate exceeded pre-drug control 
after 10 days, and blood pressure did not significantly elevate. The subjects 
themselves only reported mild hot flashes and chills during the first 14 days 
of the withdrawal period, then on about day 15 they experienced more of the 
typical symptoms seen during the classic opiate withdrawal syndrome, 
although these symptoms were reported as being mild. 
The ability of chronically administered buprenorphine to block the 
acute physiologic and subjective effects of morphine was also evaluated by 
these investigators. They found that the effects of 15, 30, 60, 85, and even 
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120 mg. doses of morphine were significantly attenuated when given to the 
five subjects on day 18 of the chronic buprenorphine administration phase. 
Furthermore, the attenuation of morphine’s effect (at the 30 mg. dose) lasted 
for 29 hours after placebo was substituted for buprenorphine. 
Based on the results described above, Jasinski et al. (1978) conclude 
that buprenorphine's action in humans is consistent with a long acting partial 
opiate receptor agonist. They suggest that buprenorphine would be suitable 
as a maintenance type therapy for the treatment of illicit opiate addiction due 
to its long duration of action, acceptance by addicts, low level of physical 
dependence, and ability to block the action of added opiates. 
Buprenorphine's ability to achieve blockade of opioid agonist effects in 
humans is dose dependent (over a range of 2 to 16 mg./day s.l.), and 
subjective effects appear to be attenuated to a greater degree than 
physiologic effects (Bickel et al., 1988a). Similarly, naltrexone has been 
shown to be more effective in blocking the subjective effects of opioids than 
the physiologic effects such as the production of miosis (Verebey, 1977). 
Buprenorphine has been shown to be an effective blocker of opioid effects 
for 24 to 29 hours after the last dose of buprenorphine, and the respiratory 
depressive effects of buprenorphine and other opioids is not additive (Bickel 
et al., 1988a; Jasinski et al., 1979). 
A dose of buprenorphine (0.3 mg./7Q kg. i.v.) produces respiratory 
depression, as measured by the reduction of indexes of carbon dioxide 
responsiveness to one half of their control values in humans. This 
respiratory depressive effect cannot be reversed by a relatively large dose of 
naloxone (1 mg.), and doses of 5 and 10 mg. are required. The time course 
of naloxone’s reversal of buprenorphine's effect is prolonged (up to three 

hours) when compared to morphine, in which naloxone produces almost 
instantaneous reversal of effect (Gal, 1989). 
Clinical Use of Buprenorphine: In a study to evaluate the 
effectiveness of buprenorphine as a maintenance therapy for opiate 
addicted persons, Mello and Mendelson (1980) studied buprenorphine's 
ability to suppress heroin use by heroin addicts. The study subjects, who 
were male heroin addicts, were given either 4 mg./day of buprenorphine, 8 
mg./day of buprenorphine, or placebo. The subjects were allowed to earn 
either money or up to three doses of heroin per day through work at a simple 
operant task. The investigators found that the group of patients maintained 
on 8 mg./day of buprenorphine took 69% to 98% less heroin than the control 
group, and that the degree of suppression of heroin self-administration was 
related to the maintenance dose of buprenorphine, as the 4 mg./day of 
buprenorphine group took 45% less heroin than the controls. During a 30 
day observation period after the gradual discontinuation of buprenorphine 
maintenance, none of the study subjects reported any signs or symptoms of 
opiate withdrawal. The authors conclude that buprenorphine is an 
extremely effective agent in suppressing heroin use by heroin addicts. It is 
preferable to methadone maintenance since buprenorphine produces a 
minimal withdrawal syndrome upon discontinuation, and it should therefore 
be easier to stop buprenorphine maintenance than methadone maintenance 
(Mello and Mendelson, 1980). Another advantage of buprenorphine over 
methadone in maintenance therapy is the relative safety of buprenorphine, 
as its antagonist component appears to lessen the risk of lethal overdose 
(Lewis et al., 1982). 
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Buprenorphine is equally effective as the pure antagonist naltrexone 
in suppressing heroin self-administration in heroin addicts. In a separate 
study utilizing identical experimental conditions as those described above 
(in Mello and Mendelson, 1980), Mello et al. (1981) found that heroin addicts 
maintained on naltrexone took between 2.5% and 7.5% of available heroin. 
This is similar to the results reported above (Mello and Mendelson, 1980) for 
buprenorphine, in which the heroin addicts used between 2% and 16% of 
the available heroin. The authors suggest that buprenorphine's advantages 
over naltrexone include greater acceptability of buprenorphine by addicts, 
as evidenced by the difficulty experienced in retaining heroin addicts in 
naltrexone treatment programs (Resnick and Washton, 1978). 
From a practical standpoint, buprenorphine is well suited to fit into 
detoxification protocols since it can be effectively administered by the 
sublingual route. In fact, buprenorphine doses are a bit more potent when 
delivered sublingually compared to subcutaneously: 1 mg. s.l. = 0.65 mg. 
s.c. (Jasinski et al., 1989). The sublingual preparation of buprenorphine has 
been shown to be effective at a dose of 4 mg./day as a maintenance therapy 
for opiate-dependent persons (Seow et al., 1986). 
Based on results obtained in opiate-addicted non-human primates, 
which indicate that buprenorphine is significantly more effective than 
methadone in suppressing opiate self-administration (Mello et al., 1983), 
Bickel et al. (1988b) attempted this comparison in humans. In a randomized, 
double-blind, placebo controlled study, Bickel et al. administered either 2 
mg. s.l. of buprenorphine or 30 mg. p.o. of methadone to the study subjects, 
who were 45 heroin addicted persons. The subjects received these 
medications for 3 weeks, then underwent dose reductions for 4 weeks, and 
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then received 6 weeks of placebo medication. During this course the 
patients were observed for direct drug effects and for signs of withdrawal. 
The authors found that buprenorphine had sufficient agonist activity to make 
it as effective as methadone in detoxification of opioid addicts. There was no 
significant difference found between groups in terms of subject retention, 
illicit opiate use, or withdrawal signs and symptoms. Buprenorphine is 
equally effective as methadone in achieving opiate detoxification, but may 
be preferable based on its unique pharmacological properties. 
Based on the evidence presented above that buprenorphine is able 
to substitute for other opiates without precipitating withdrawal, and that it 
produces a low level of physical dependence with a mild withdrawal 
syndrome produced upon its discontinuation, Kosten and Kleber (1987) 
undertook an open study in an outpatient setting to evaluate buprenorphine 
as a drug to be used as a transitional agent between methadone or heroin 
and the drug-free state. The study patients, who were 8 methadone- 
maintained persons (25 mg./day) and 8 heroin-addicted persons, were 
discontinued from their opioid and administered either 2, 4, or 8 mg. s.l. of 
buprenorphine daily. After 30 days of receiving buprenorphine, the drug 
was abruptly discontinued. Throughout the study the patients were 
evaluated daily for signs and symptoms of opiate withdrawal, and 
periodically for the presence of illicit opiates in the urine. Treatment 
retention was 81%, with 13/16 patients successfully completing the 
detoxification protocol. Illicit opioid use was minimal, with 3 patients who 
were completely abstinent, and 10 patients who used illicit opioids only once 
or twice. No differences for illicit opioid use were found between the 2 and 4 
mg. groups. Only one patient in the 8 mg. group used illicit opioids. 
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The mild withdrawal symptoms that were observed declined (14.5 to 
8.6 out of possible 72 point scale) for the entire study group during the 
course of the study, with no significant difference between the patients 
coming from methadone maintenance and from heroin. However, this 
overall decrease in withdrawal symptoms was due to the 4 mg. group, since 
the patients in the 8 mg. group reported symptom levels similar to the 2 mg. 
group, both of which remained constant and were higher than the 4 mg. 
group. After the abrupt discontinuation of buprenorphine, only the 8 mg. 
group showed a significant increase in withdrawal symptoms score. After 
stopping buprenorphine, the 13 patients who successfully completed the 
detoxification were drug-free, and 7 of them initiated naltrexone therapy, 
which did not precipitate any withdrawal symptoms. The apparent similarity 
in withdrawal scores between the 2 and 8 mg. groups, which were both 
higher than the 4 mg. group, suggests a bell-shaped dose-response curve 
for buprenorphine's ability to suppress withdrawal symptoms in opioid 
addicts. The peak withdrawal symptoms experienced by the study patients 
were comparable to those experienced by patients successfully detoxified 
with clonidine, and compared favorably to those experienced by patients 
who failed clonidine detoxification (Charney et al., 1982; Kleber et al., 1987). 
Furthermore, the success rate of initiating naltrexone therapy was 
significantly higher in the present study with buprenorphine than was 
previously obtained with clonidine alone or with a 30 day methadone taper 
(Rounsaville et al., 1985). Kosten and Kleber conclude that buprenorphine 
at 2 to 4 mg. s.l. is an effective transitional agent for the outpatient 
detoxification of methadone or heroin addicts. 
. 
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Subsequent studies have supported the above conclusions that opioid 
addicts may undergo rapid induction into a buprenorphine treatment plan 
without the precipitation of withdrawal symptoms, with a high rate of 
successful treatment outcome, and with only mild withdrawal symptoms 
produced upon transition to the drug-free state (Johnson et al., 1989; Fudala 
et al., 1990). 
Purpose of this Clinical Investigation: The difficult but important 
goal of achieving opiate detoxification has been reached successfully with 
clonidine, a combination of clonidine plus naltrexone, and buprenorphine. 
In the present study, clonidine was used to suppress symptoms during 
opiate withdrawal, a combination of clonidine plus naltrexone was used to 
achieve rapid opiate detoxification, and buprenorphine was used as a 
transitional agent between the opioid-addicted state and the initiation of 
naltrexone therapy. The purpose of the present study is to directly compare 
these three methods of opiate detoxification by means of a randomized trial 
in an outpatient setting. Previous evaluations of each of these three 
methods of opiate detoxification were carried out at either inpatient or 
outpatient substance abuse treatment centers. The present study is unique 
in that it was carried out at a primary care medical center. It is hoped that the 
protocols developed here will be effective and suitable for use by primary 
care physicians who are not necessarily working at substance abuse 
treatment centers. Integrating opiate detoxification into a general medicine 
practice would allow for greater accessibility of detoxification for a 
physician's patients, and may also facilitate the incorporation of intravenous 
drug users into the health care system. 

MATERIALS AND METHODS 
Location of Study: The detoxification procedures were carried out at 
the Central Medical Unit (CMU) of the Yale Substance Abuse Treatment 
Unit (SATU), located in New Haven, Connecticut. The CMU is a primary 
care medical clinic which serves members of the surrounding community. 
Patients who were enrolled in the present study were also eligible for 
medical care through the CMU, free of charge. After successful 
detoxification, study patients were referred to SATU Outpatient Services 
(SOS), which is an affiliated relapse prevention program which offers 
naltrexone maintenance therapy and weekly support group meetings. 
Members of the staff of the CMU carried out the detoxification procedures 
used in this study, and also recorded the baseline and daily assessment 
parameters. The coding form used to organize the data collected was 
designed by Dr. Patrick O'Connor. Collection, organization, and analysis of 
the data was carried out by this author. 
Subjects: The patient group included opiate-addicted persons who 
requested opiate detoxification and who were referred to the Central 
Medical Unit (CMU) clinic of the Yale Substance Abuse Treatment Unit 
(SATU) from various community outreach programs and health centers. A 
major source of referral was the Community Health Education Project 
(CHEP). The patients used illicit opiates intravenously or intranasally. 
Eligible patients included those who were age 18 to 65, were addicted 
to opiates and not currently in treatment, were willing to be referred to a 
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relapse prevention program after detoxification, and who had sufficient 
social support to comply with an outpatient program, including daily 
transportation to and from the clinic. 
Exclusion criteria included: 1) pregnancy, 2) known allergies to any of 
the study medications, 3) history of significant medical condition including 
hypertension, baseline hypotension (systolic blood pressure below 90 mm 
Hg), active cardiac disease, uncompensated asthma, possible volume 
depletion secondary to other illnesses, active hepatitis, other significant 
medical conditions identified on baseline medical examination, 4) history of 
a severe psychiatric disorder (e.g., major psychotic episode or depression, 
schizophrenia), 5) current primary dependence on alcohol or drugs other 
than opiates or cocaine. Patients who were HIV positive and asymptomatic 
were not excluded from the study. 
The study patients were in good health as evidenced by medical 
history, physical exam, psychiatric evaluation, and laboratory analysis 
including serum electrolytes, renal function, liver function, CBC, urinalysis, 
serum pregnancy test for women, hepatitis serology, syphilis serology, HIV 
testing, tuberculosis screening. 
Baseline Assessments: Medical and psychiatric evaluations as above. 
Each patient's prior drug use history and prior drug treatment history was 
obtained. Patients who were referred through CHEP completed an AIDS 
Initial Assessment (AIA) survey prior to referral. Addiction Severity Index 
(ASI), baseline symptom severity scale, baseline craving score, urine 
toxicology (for opiates, cocaine, benzodiazepines, barbiturates, THC), and a 
modified Beck Depression Inventory score (13 items designed to assess 
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degree of psychologic depression, scored 0 (none) to 3 (severe); maximum 
score = 39; score of <10 correlates with the absence of clinical depression) 
were also obtained prior to initiation of the detoxification protocols. 
Daily Assessment Instruments: Systolic and diastolic blood pressures were 
measured at the beginning of each study day, and periodically during the 
course of each day for each patient as needed. Prior to receiving the daily 
medication, each patient completed a visual analogue opiate craving scale 
to assess present craving and peak craving over the previous 24 hours. The 
analogue craving scale consisted of a horizontal line with the left end 
marked "0, no craving", the middle marked "50", and the right end marked 
"100, intense craving" (Horwitz et al., 1989). The severity of 24 withdrawal 
symptoms (e.g., muscle aches, chills, restlessness) was rated with a score of 
O (none) to 3 (severe) for current symptoms and for peak symptoms 
experienced over the previous 24 hours. The maximum score on the 
symptom severity scale was 72 (Kosten and Kleber, 1987). Each patient 
was also questioned about any intercurrent drug use, and urine toxicology 
was obtained on day 5. 
Treatment Protocols: Eligible patients were randomly assigned to one 
of three treatment protocols. "Block" randomization was performed, three 
patients per week were to begin detoxification, and one patient was 
randomized to each of the three protocols. This method of randomization 
was performed in order to evenly distribute the number of symptomatic 
patients throughout the week, and therefore efficiently utilize the resources 
of the CMU staff. The greatest degree of withdrawal symptomatology would 
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be expected on days when patients receive naltrexone. As designed, 
patients in the clonidine/naltrexone group should therefore experience 
maximum symptoms early in the week, patients in the buprenorphine group 
should experience maximum symptoms later in the week, and patients in the 
clonidine group should not experience the acute onset of withdrawal 
symptoms on any particular day. All of the detoxifications began on a 
Monday at 8:30 a.m.. In addition to the medication regimens described 
below, patients were administered a short acting benzodiazepine 
(oxazepam, 30 mg. every 4 to 6 hours, maximum dose 120 mg. in 24 hours) 
as needed to control muscle cramps, anxiety and insomnia during 
detoxification. Painful muscle cramps were also treated, if needed, with the 
anti-inflammatory medications ibuprofen or ketorolac. A summary of each 
treatment protocol is provided in Table I. 
A) Clonidine Detoxification: This procedure took place over a 10 day 
period. Dav 1: Clonidine 0.2 mg. p.o. was given at approximately 8:30 a.m.. 
Blood pressure was checked every 15-60 minutes while patients remained 
in the clinic. Patients were required to remain in the clinic for 4 hours, longer 
if symptomatic, and were then discharged with enough clonidine to take up 
to a total of 1.2 mg. (0.2 mg. every 4-6 hours) until the next clinic visit at 8:30 
a.m. on day 2. Davs 2-7: Patients were seen at the clinic daily in the 
mornings of weekdays and were administered clonidine, dosage adjusted 
according to their symptoms. Patients were given an appropriate amount of 
medication to be taken at home on the weekends. Blood pressure was 
monitored periodically for one hour while the patients remained in the clinic. 
Patients were then discharged each day with an appropriate amount of 
clonidine for their symptoms, clonidine doses were tapered appropriately as 
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patients' symptoms lessened. Days 8-10: Referral and initiation of relapse 
prevention activities began. If the patients had been opiate-free as 
assessed by history and urine toxicology, naltrexone therapy was initiated 
on day 8 with 25 mg. p.o. of naltrexone. Patients received 50 mg. of 
naltrexone on subsequent days if they remained asymptomatic, and were 
referred for naltrexone maintenance therapy at SOS. 
B) Clonidine/Naltrexone Detoxification: This procedure took place over 
a 4-5 day period. Dav 1: Clonidine 0.2 mg. was administered at 
approximately 8:30 a.m., and then every 2-4 hours throughout the day for a 
maximum dose of 1.8 mg.. Naltrexone 12.5 mg. p.o. was administered 
approximately 1 hour after the initial clonidine dose. Patients were required 
to spend the entire day at the clinic, with blood pressure checks every 30-60 
minutes. Patients were discharged home with enough clonidine to take up 
to a maximum of 1.2 mg. until returning to the clinic at 8:30 a.m. on day 2. 
Dav 2: Clonidine dosing as on day 1. Patients received 25 mg. of 
naltrexone, and were monitored for 4 hours. Patients were allowed to leave 
the clinic at that time if their withdrawal symptoms were well controlled, and 
received the appropriate amount of clonidine for their symptoms to be taken 
while at home. Davs 3-5: Clonidine doses tapered appropriately as 
patients' symptoms lessened. Patients received 50 mg. of naltrexone on 
each of these days, and were sent home with appropriate tapering doses of 
clonidine. Patients who were successfully detoxified by day 5 were then on 
a maintenance dose of naltrexone (50 mg./day) and were referred for 
continuing naltrexone therapy at SOS as above . 
C) Buprenorphine Detoxification: This procedure took place over a 5 day 
period, and was designed to allow three days of buprenorphine 
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administration as a transition period from illicit opiate use to the initiation of 
naltrexone therapy. Days 1-3: Patients were administered 3 mg. s.l. of 
buprenorphine at approximately 8:30 a.m. and were monitored for any 
withdrawal symptoms for several hours. If asymptomatic, patients were 
discharged home. Dav 4: Patients who reported being free from illicit opiate 
use for the first three days were allowed to continue. They then received 
clonidine 0.2 mg. at approximately 8:30 a.m., followed by naltrexone 25 mg. 
p.o. one hour later. Patients were required to stay in the clinic throughout 
the day, and blood pressure was monitored every 30-60 minutes. Clonidine 
0.2 mg. was administered every 2-4 hours as needed to suppress any 
withdrawal symptoms. Patients were discharged with an appropriate 
amount of clonidine to control their symptoms until returning to clinic at 8:30 
a.m. on day 5. Dav 5: Patients received 50 mg. of naltrexone. Clonidine 
dosing was tapered to 0 mg. as patients' symptoms lessened. Patients who 
were successfully detoxified by day 5 were on a blocking dose of naltrexone 





One hundred patients were enrolled in this study. Three patients who 
were initially enrolled failed to show up for day one of detoxification, and 
were therefore not included in subsequent analyses. Through the 
randomization procedure described above, 31 patients were assigned to the 
clonidine group, 33 patients were assigned to the clonidine/naltrexone 
group, and 33 patients were assigned to the buprenorphine group. 
The sociodemographic characteristics of the study patients are 
presented in Table II. Overall, there were 71% men, 57% high school 
graduates, 52% unemployed persons, 12% Blacks, 32% Hispanics, and 
56% Whites. The mean age (± SD) of the patients enrolled was 32 years (± 
6.8), and there was no statistically significant difference in age between the 
study groups (One-way ANOVA F(2,92)=1.98, p=0.14). 
The past substance abuse histories of the overall study group are 
displayed in Table III. All of the study patients (100%) were heroin users 
and/or users of a currently available short-acting synthetic opiate referred to 
as “p-dope”. The overall mean age of first drug use (any drug except 
alcohol) was 18 years (± 8.6). The overall mean age of first injection of a 
drug was 23.4 years (± 10.6). For the entire study population, the mean age 
of first heroin use was 22.4 years (± 6.5) with 80% using heroin 
intravenously. The mean duration of heroin use was 10.6 years (±8.6). 
Thirty-five percent (35%) of the intravenous drug users reported sharing 
needles during the six months prior to enrolling in the study. Ninety-three 
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percent (93%) of the study subjects were also users of cocaine; their mean 
age of first cocaine use was 23.2 years (± 7.2), and 60% of these subjects 
had used cocaine intravenously. The percentage of patients using heroin 
once or more per day, 42%, was greater than the percentage of patients 
using cocaine once or more per day, 12%. Almost all (92%) of the patients 
reported using alcohol, with the mean age of first alcohol use being 17 years 
(± 12.5). The mean number of previous opiate detoxification attempts by the 
study population was 0.8 (±_ 1.7), with a range of 0 to 20 previous attempts. 
A selected portion of the medical histories of the study patients is 
presented in Table IV. Overall, 33% of the patients reported having a source 
of primary medical care prior to entering the study. Of the 14 patients tested 
for HIV, 7 (50%) were HIV positive. Of the 97 patients tested for evidence of 
past exposure to the hepatitis B virus, 30 (32%) were found to have a 
positive test for hepatitis B surface antibody. Ninety-seven (97) of the study 
patients were tested for exposure to Treponema pallidum with the rapid 
plasma reagin (RPR) test. Five (5%) of those tests were positive, with 2 (2%) 
subsequent positive results on the fluorescent treponemal antibody (FTA) 
test. 
Results of the baseline assessments obtained for each study group 
are presented in Table V. For the entire study population, the mean Beck 
Depression Inventory score (maximum score = 39) was 10.9 (±5.6), and 
there was no statistically significant differences between the Beck’s scores of 
each of the study groups (F(2,70)=1.4, p=0.3). The overall mean baseline 
craving score (maximum=100) was 73.9 (± 32.4). The mean baseline 
craving scores for each of the study groups were similar, and not statistically 
different from each other (F(2,88)=1.3, p=0.27). The overall mean baseline 
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symptom severity score (maximum=72) was 16.2 (± 13.2). The study groups 
did not differ significantly from each other in terms of their mean baseline 
symptom severity score (F(2,84)=1.6, p=0.2). Eighty-three (83) patients had 
baseline urine toxicologies assessed, and 49% of the results were positive 
for the presence of cocaine. 
The outcome of the detoxification procedures is presented by study 
group in Table VI. Overall, 68 (70%) of the patients successfully completed 
their respective protocols and were detoxified from illicit opiates at the end of 
their protocol. A detoxification was classified as successful if the patient was 
able to take a blocking dose of naltrexone (50 mg.) without demonstrating 
any signs or symptoms of withdrawal, and had completed the clonidine taper 
to 0 mg./day. The clonidine group had a success rate of 48%, the 
clonidine/naltrexone group had a success rate of 82%, and the 
buprenorphine group had a success rate of 79%. The success rate of the 
clonidine group was less than that of the clonidine/naltrexone group and 
buprenorphine group, (respectively: chi-square=7.92, d.f.=1, p<0.005; chi- 
square=6.42, d.f.=1, p=0.01). There was no statistically significant difference 
in success rate between the clonidine/naltrexone group and the 
buprenorphine group (chi-square=0.096, d.f.=1, p=0.76). A similar number 
of successful relapse prevention referrals were made for each study group. 
Of the 68 successful detoxifications, 51 (75%) were successfully referred for 
relapse prevention. A relapse prevention referral was defined as being 
successful when the patient agreed to enroll in the naltrexone maintenance 
relapse prevention program at SATU Outpatient Services, and then actually 
began that program. 
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The overall mean length of detoxification for successful patients in the 
entire study group was 6.9 days (± 2.7). The mean duration of detoxification 
for successes in the clonidine group was 8.6 days (± 2.2), for the 
clonidine/naltrexone group it was 4.9 days (± 1.5), and for the 
buprenorphine group it was 8.2 days (± 2.7). The duration of detoxification 
for successful patients in the clonidine/naltrexone group was significantly 
shorter than for the clonidine group and for the buprenorphine group (t=5.69, 
p<0.Q001; t=5.84, p<0.0001). There was no significant difference between 
the duration of detoxification of successful patients in the clonidine and 
buprenorphine groups (t=0.53, p>0.6). 
The most common reason for detoxification failure, representing 66% 
of all failures, was a failure of the patient to return to the clinic to complete 
the protocol. Drug use (by history) was less common (10%). Six (6) patients 
in the clonidine group who were judged to be failing this protocol on the 
basis of persistent symptoms and/or drug use were reassigned to an 
alternative method of detoxification. These six patients were included as 
protocol failures in this analysis. The patients who were successfully 
detoxified in each study group required similar amounts of Serax to control 
muscle cramps, anxiety and insomnia during the detoxification procedure 
(F(2,65)=1.7, p=0.20). 
The results of the daily assessment measures during the first five days 
of detoxification are presented in the figures. Figure I displays the trends of 
the mean current symptom severity scores of each of the study groups. The 
overall trend was toward lower current symptom severity scores over time, 
although only the clonidine group demonstrated a statistically significant 
difference between the mean current symptom severity score on day 1 and 
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day 5 (t=2.27, p<0.05). The buprenorphine group was the only group whose 
mean current symptom severity score did not rise above the baseline (day 1) 
value during the course of the detoxification. Also, there was a significant 
decrease in the mean current symptom severity score for the buprenorphine 
group between days 1 and 3 (t=2.70, p<0.01). The mean current symptom 
severity scores between the groups did not differ significantly for the first five 
days of detoxification. 
Figure II shows the trends of the mean peak symptom severity scores 
for each study group that were attained during the twenty-four hour period 
preceding each study day. These scores therefore represent the magnitude 
of the worst daily withdrawal symptoms experienced by the study patients 
during detoxification. As expected, the process of opiate detoxification 
produced an increase in the severity of the peak withdrawal symptoms 
experienced by the study subjects. However, the overall severity of 
withdrawal symptoms experienced was relatively mild, with the highest 
mean peak symptom severity score (maximum score = 72) for all study 
patients being 18.9 (+ 13.6) on day 2. The clonidine/naltrexone group had 
the highest mean peak symptom severity scores during the course of the 
study, and achieved the highest overall mean score of 25.8 (± 15.7) on day 
3. The buprenorphine group experienced a significant increase in mean 
peak symptom severity score between days 3 and 5, which was the period of 
transition from buprenorphine to naltrexone therapy (t=2.24, p<0.05). There 
was a statistically significant difference between the mean peak symptom 
severity scores of the study groups on days 3. (F(2,72)=6.7, p<0.005). This 
difference was due to the higher score of the clonidine/naltrexone group on 
day 3 compared to the clonidine and buprenorphine groups (t=1.88, p=0.06; 
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t=3.51, p<0.005). By day 5, both the clonidine/naltrexone group and the 
buprenorphine group had mean peak symptom severity scores that were 
significantly higher than they were on day 1 (t=2.09, p<0.05; t=2.03, p<0.05), 
indicating that on average, these groups were still experiencing increased 
withdrawal symptoms during the period of day 4. By day 5 the clonidine 
group was beginning to show a decline in severity of peak symptoms, 
although this score was not yet significantly lower than the mean peak 
symptom severity score of the group on day 1 (t=0.82, p=0.60). 
The mean current craving scores obtained from the visual analogue 
craving scale for each group are presented in Figure III. The overall trend 
was for decreasing degrees of craving as the detoxification protocols 
progressed, and by day 5 each of the study groups had a significantly lower 
mean current craving score than they had on day 1 (clonidine, t=3.29, 
p<0.005; clonidine/naltrexone, t=2.03, p<0.05; buprenorphine, t=3.54, 
p<0.005). There was a significant difference of mean current craving score 
on day 1 between the study groups (F(2,88)=4.9, p=0.01), and this difference 
was due to the higher score of the buprenorphine group compared to the 
clonidine and clonidine/naltrexone groups (t=2.82, p<0.01; t=2.65, p=0.01). 
During days 2 through 5, the study groups did not differ significantly in terms 
of their mean current craving score. 
Figure IV displays the peak craving score obtained by each study 
group during the 24 hour period preceding each study day. As with current 
craving scores discussed above, the mean peak craving scores decreased 
during the course of the study. By day 5, each of the study groups had a 
significantly lower mean peak craving score than they had on day 1 
(clonidine, t=4.90, p<0.0001; clonidine/naltrexone, t=2.95, p<0.005; 
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buprenorphine, t=6.53, p<0.0001). There was no significant difference 
between the groups in terms of their mean peak craving score on days 1 
through 5. 
Changes in mean systolic blood pressure of the patients in each 
study group during detoxification are shown in Figure V. The overall trend 
was toward lower systolic blood pressures as the detoxification protocols 
progressed. Both the clonidine group and the buprenorphine group had a 
statistically significant decrease in mean systolic blood pressure between 
days 1 and 5 (t=2.88, p<0.005; t=2.81, p<0.01). The clonidine and 
clonidine/naltrexone groups (both of which received clonidine on day 1) 
showed a significant decrease in mean systolic blood pressure between 
days 1 and 2 (t=3.86, p=0.001; t—3.58, p<0.005), while the buprenorphine 
group did not show a significant drop in mean systolic blood pressure on 
day 2 (t—1.33, p=0.19). The mean systolic blood pressure of the 
buprenorphine group remained higher than that of either the clonidine group 
or clonidine/naltrexone group (significantly so on day 2, F(2,79)=7.6, 
p=0.001; and day 4, F(2,65)=8,5, p=0.001) until day 5, which was one day 
after initiation of clonidine administration in the buprenorphine group, 
interestingly, the buprenorphine group showed a small increase in mean 
systolic blood pressure between days 3 and 4 which was the period of 
transition from buprenorphine to naltrexone and clonidine administration. 
During the course of the study, there were no episodes of symptomatic 
changes in systolic blood pressure that required treatment. 
' 
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Table I Outline of Protocol Medication Administration 
Detoxification Day 
T reatment 1 2 3 4 5 6 7 8 9 1 0 
Protocol 
Clonidine C C C C C C C C N N 
Clonidine/ C,N C,N C,N C,N C,N C,N C,N C,N N N 
Naltrexone 
Buprenorphine B B B C,N C,N C,N C,N C,N N N 
C = Clonidine; N = Naltrexone; B = Buprenorphine 
Study Medication Dosages: 
Clonidine: 0.2 ma. p.o. everv 4 to 6 hours, 
maximum dose = 1.2 mg./day. 
Naltrexone: 12.5 to 50 ma. p.o. everv dav. 
maximum dose = 50 mg./day. 
Buprenorphine: 0.3 ma. s.l. everv dav. 
maximum dose = 0.3 mg./day. 
Adjunct Therapies (given as needed): 
oxazepam 15 to 30 ma. p.o. everv 4 to 6 hours, 
ibuprofen 300 to 600 ma. p.o. everv 4 to 6 hours, 
ketorolac 30 mg. i.m. every 6 hours. 
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Table II Overall Sociodemographic Characteristics of 
the Study Patients 
Characteristic Patient Value 
(N=97) 
Men, n (%) 69 (71) 
Age, yr. (mean + SD) 32 ±6.3 
High School 
Graduates, n (%) 
55 (57) 
Unemployed, n (%) 
Race: Black, n (%) 
50 (52) 
12 (12) 
Hispanic, n (%) 31 (32) 
White, n (%) 54 (56) 
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Table III Substance Use History of the Study Patients 
Feature Patient Value 
(N=97) 
General Use History: 
Age 1st. Drug Use, yr. 
(mean ± SD) 
18.0 ± 8.6 
Age 1st. Injection, yr. 
(mean ± SD) 
23.4 ± 10.6 
Intravenous Drug Users 
Who Shared Needles, Past 
6 mo., n (%) 
46 (35) 
Heroin: 
Users, n (%) 97 (100) 
Intravenous Users, n (%) 78 (80) 
Age 1st. Use, yr. 
(mean ± SD) 
22.4 ± 6.5 
Use > Once per Day, n (%) 41 (42) 
Duration of Use, yr. 
(mean + SD) 
10.6 ± 8.6 
Cocaine: 
Users, n (%) 90 (93) 
Intravenous Users, n (%) .54.(60). 
Age 1st. Use, yr. 
(mean ± SD) 
23.2 ± 7.2 
Use > Once per Day, n (%) 11 (12) 
Alcohol: 
Users, n (%) 89 (92) 
Age 1st. Use, yr. 
(mean + SD) 
17.5 ± 12.5 
Treatment Mobility: 
Prior Detoxifications, n 
(mean ± SD) 
0.8 ± 1.7 
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Table IV Medical History of the Study Patients 
Feature Patient Value 
(N=97) 
With Source of 
Primary Care, n (%) 
32 (33) 
Tested for HIV, n (%) 14 (14) 
HIV + , n (%) 7 (50) 
HBsAB + , n (%) 
FTA + , n (%) 2 (2) 
HIV = Human Immunodeficiency virus; 
HBsAB = Hepatitis B surface antibody; 
FTA = Fluorescent treponemal antibody 
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(mean ± SD) 
12.0 ± 6.9 11.6 ± 5.1 9.6 ± 4.7 10.9± 5.6 
Baseline Craving 
Score (mean ± SD) 
66.3 ± 31.9 74.1 + 33.3 80.0 ± 31.5 73.9 ± 32.4 
Baseline Symptom 
Severity Score 
(mean ± SD) 
13.1 ± 10.5 15.7 ± 13.1 19.4 ± 14.9 16.2 ± 13.2 
Baseline Urine 
Toxicology Positive 
for Cocaine (% + of 
patients tested) 
39 56 53 49 
C = Clonidine; C/N = Clonidine/Naltrexone; B = Buprenorphine 
There were no statistically significant differences between the 
groups for the baseline assessments listed in the Table. 
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Table VI Outcome of Detoxification Protocols 
Outcome Measure C 








Detoxification, n (%) 
15 (48) * 27 (82) 26 (79) 68 (70) 
Successful Relapse 
Prevention Referral, 
n (% of successful 
detoxifications) 
14 (93) 19 (70) 18 (69) j 51 (75) 
Reason for 
Detoxification 

























(mean ± SD) 




(mean ± SD) 
617 ± 421 459 ± 302 602 ± 298 548 ± 333 
C = Clonidine; C/N = Clonidine/Naltrexone; B = Buprenorphine 



























# = Score on day 5 is significantly lower than day 1 


























f = Score on day 5 is significantly higher than day 1 
# = Score on day 5 is significantly higher than on days 3 and 1 















Fig. Hi Current Craving Score 
Day 
# = Score on day 5 is significantly lower than on day 1 















Fig. IV Peak Craving Score, past 24 hr. 



































# = Score on day 5 is significantly lower than day 1 
t = Score on day 2 is significantly lower than day 1 




Each of the three methods of opiate detoxification examined in this 
study allowed the study patients to withdraw from illicit opiates and initiate 
naltrexone maintenance therapy with considerable success (70% successful 
detoxification, 75% successful relapse prevention referrals). This high 
overall success rate, combined with the fact that there were no serious 
medical complications from the detoxification procedures, indicates that 
these methods of opiate detoxification can be effectively and safely carried 
out in an outpatient, primary care setting. 
The success rate of the clonidine protocol in this study, 48%, 
compares favorably to previous outpatient evaluations of this type of 
detoxification procedure in terms of achieving detoxification from heroin. 
Washton and Resnick (1980a) reported a success rate of 80% during their 
evaluation of clonidine as an agent for managing methadone withdrawal, 
but observed only a 36% success rate for the same protocol when heroin 
addicts were studied. Other outpatient evaluations of clonidine have utilized 
either methadone-addicted persons or heroin addicts, and the success rates 
reported range from 31% to 43% (Washton and Resnick, 1980b; Kleber et 
al., 1985; O’Connor et al., in press). 
An interesting feature of the study carried out by O’Connor et al. 
(which was performed at the same location and with similar protocols as the 
present study), was that in O’Connor’s study the patients were allowed to 
choose between a clonidine detoxification protocol and a 
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clonidine/naltrexone protocol. In that study, 64% of the patients chose 
clonidine, and 36% chose clonidine/naltrexone. The success rate for the 
clonidine protocol was 43%, and for the clonidine/naltrexone protocol it was 
95%. By allowing the patients to choose their protocol, patients who were 
possibly less motivated and therefore unwilling to undergo a potentially 
more uncomfortable clonidine/naltrexone protocol could have selected the 
clonidine protocol. The present study eliminated this bias by randomizing 
patients to each treatment group; patients with varying degrees of motivation 
were therefore equally distributed to each group. The higher success rate of 
the clonidine protocol in this study when compared to that observed by 
O’Connor could be due to the randomization procedure carried out in the 
present study. The high rate of successful relapse prevention referral 
obtained by the clonidine group in the present study (93%) in comparison to 
the other treatment groups may also be explained by selection out of highly 
motivated patients. Patients who were successful in the clonidine protocol 
may represent a subset of patients who were highly motivated and 
dedicated to achieving successful detoxification, as they were compliant with 
a long detoxification protocol. This may have made them more likely to 
follow through to a relapse prevention program. 
Although O’Connor’s study achieved a lower successful detoxification 
rate for the clonidine group, the clonidine/naltrexone group in that study had 
a higher success rate (95%) than that achieved by the clonidine/naltrexone 
group in the present study (82%). Again, allowing patients to choose their 
method of detoxification allows highly motivated patients to choose a 
method such as clonidine/naltrexone, which works quickly but with 
potentially greater discomfort. The lower success rate seen in the 
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clonidine/naltrexone group in this study could in part be due to the 
randomization procedure, which assigned patients with low motivation to a 
potentially rigorous method of detoxification. Reports from other authors of 
success rates for a clonidine/naltrexone protocol range from 82% to 95% 
(Charney et al., 1986; Kleber et al., 1987; Vining et al., 1988). These studies 
include inpatient and outpatient evaluations utilizing methadone and heroin 
addicted persons. Of importance is that these studies evaluated the 
effectiveness solely of a clonidine/naltrexone protocol. Therefore, by 
consenting to enter these studies, the patients in effect chose to undergo a 
detoxification with clonidine/naltrexone. The present study, which is the only 
known evaluation of a clonidine/naltrexone protocol to which patients were 
assigned, indicates a lesser degree of success for the clonidine/naltrexone 
protocol. It appears that allowing patients to choose their method of 
detoxification has a favorable outcome on results when a 
clonidine/naltrexone protocol is being considered. This observation may be 
helpful to primary care physicians who attempt to utilize this highly 
successful method of opiate detoxification in their practices. When patients 
are offered a clonidine/naltrexone detoxification, an alternative method of 
detoxification should also be offered since the present study suggests that if 
patients are assigned to clonidine/naltrexone they do less well than patients 
who freely choose clonidine/naltrexone. 
The success rates of detoxification (79%) and relapse prevention 
referral (69%) obtained by the buprenorphine group in this study are 
comparable to the success rates reported in a previous investigation. 
Kosten and Kleber (1988) evaluated a thirty day buprenorphine 
detoxification protocol in an outpatient setting utilizing methadone and 
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heroin addicts and reported a treatment success rate of 81%, with 54% of 
their patients initiating naltrexone therapy. The remainder of the previous 
studies of buprenorphine as an agent for achieving opiate detoxification 
have centered either on using buprenorphine as a maintenance therapy or 
on the acceptability of buprenorphine to opiate addicts, and therefore cannot 
be directly compared to the present study in terms of detoxification success 
rate. Further aspects of the buprenorphine treatment group that were 
observed in the present study will be discussed later. 
A significant difference between the duration of the treatment 
protocols for successfully detoxified patients was observed. The 
clonidine/naltrexone protocol, with a mean duration of 4.9 days (+ 1.5), was 
significantly shorter than both the clonidine and the buprenorphine 
protocols. The clonidine/naltrexone protocol was designed to be 
administered over a course of five days, and therefore be a more rapid 
detoxification than the other treatment protocols. It is interesting to note that 
the patients who were successful in this protocol were able to complete 
detoxification within the designated duration of five days. In an outpatient 
setting, a shorter detoxification procedure is advantageous since it limits the 
amount of time during which a treatment failure (due to either “no show” or 
drug use) could occur. Also, the rapid protocol allows the patient to be 
placed on a blocking dose of naltrexone in a shorter amount of time, 
therefore reinforcing the decreased probability of intercurrent drug use. 
However, the use of a rapid method of opiate detoxification such as 
clonidine/naltrexone requires an intact and flexible system for relapse 




For all of the treatment groups, the most common reason for treatment 
failure was that the patient did not show up for continued evaluation. The 
significant number of “no shows” amongst the treatment failures (66%) 
highlights an important drawback of conducting outpatient opiate 
detoxification. Since patients are allowed to return home each day during 
detoxification, the stresses they normally experience at home, such as 
responsibility to children, spouse, and job become added to the stress of 
undergoing opiate detoxification. Also, patients may not be able to find a 
means of transportation to and from the clinic every day for one to two 
weeks. 
Six patients in the clonidine group were designated as treatment 
failures since they were reassigned to alternative methods of detoxification 
during the first few days of detoxification with clonidine. These patients were 
noted to be failing the clonidine protocol early in its course (i.e. symptoms 
not relieved, patient dissatisfaction, persistent drug use) and were therefore 
offered a chance for detoxification outside of the experimental protocols. 
After two or three days of clonidine only, these six patients were given 
clonidine plus naltrexone in an attempt to achieve opiate blockade earlier 
than would be allowed in the clonidine protocol. Each of these six patients 
were successfully detoxified with these alternative methods, but are included 
as failures of the clonidine protocol. 
An encouraging point might be made about the treatment failures 
observed in this study. If the detoxification protocols were carried out by a 
primary care physician on patients that were already established in his or 
her practice, then the number of failures due to "no show" might be less than 
observed here since a physician's patients have an established relationship 
' 
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with that physician prior to beginning detoxification. The strength of the 
professional relationship between physician and patient could serve to 
diffuse some of the social stresses incurred by the patient, and might 
decrease the number of failures due to "no show". The patients in this study 
were recruited specifically to undergo detoxification, and most had no 
connection with the CMU prior to detoxification. It would be interesting to 
conduct a study examining the effectiveness of the same detoxification 
protocols used here when they are applied by a single medical practice to 
patients already established in that practice. 
Each of the three treatment protocols studied here was equally 
successful in providing relief from drug craving, as demonstrated in Figure III 
and Figure IV. A greater degree of craving relief might have been expected 
from the buprenorphine protocol when compared to the others since 
buprenorphine is a partial opiate agonist and has been shown to effectively 
substitute for full agonists (Jasinski et al., 1978; Mello and Mendelson, 1980; 
Bickel et al., 1988). However, the clonidine and clonidine/naltrexone groups 
demonstrated equally significant decreases in drug craving during the 
course of the study. Previous reports that examined detoxification with 
clonidine only did not specifically assess for craving relief (Gold et al., 
1978b; Washton and Resnick, 1980a). One study that examined a 
clonidine/naltrexone detoxification procedure and specifically assessed for 
craving relief found no significant decrease in the degree of drug craving 
experienced by the patients (Vining et al., 1988). Another evaluation of a 
clonidine/naltrexone protocol that included craving as part of the symptoms 
evaluated reported no significant change in the percentage of positive 
reports of craving during the course of that study (Charney et al., 1986). 
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Drug craving is not solely a physiologic response created by hyperactivity of 
the noradrenegic autonomic system that is susceptible to amelioration by 
clonidine. Opiate craving has a subjective component to it, and this 
subjective "need" for opiates should only be fulfilled by an opiate drug, such 
as buprenorphine. It is unclear why a clonidine or clonidine/naltrexone 
protocol should provide as much relief from drug craving as a 
buprenorphine protocol. Psychologic factors such as patients’ denial of 
craving or the patients' desire to please the physician by minimizing self- 
reported degrees of craving may have contributed to the pattern of decline in 
craving scores observed in the clonidine and clonidine/naltrexone groups in 
the present study. 
All of the three methods of opiate detoxification studied here provided 
significant relief of withdrawal symptoms. Successfully detoxified patients in 
the three treatment groups were administered similar amounts of Serax to 
control symptoms such as anxiety and insomnia that were not controlled by 
the study medications. This indicates a similar degree of need for adjuvant 
medication, which is a reflection of the degree of severity of withdrawal 
symptoms experienced. The clonidine/naltrexone group experienced the 
greatest degree of symptomatology over the first five days of detoxification 
as indicated by current and peak symptom severity scores displayed in 
Figure I and Figure II. This is consistent with the proposed mechanism of 
action of this detoxification protocol, in which a short acting opiate (heroin) is 
abruptly displaced from opioid receptors by the opiate-antagonist 
naltrexone. The resulting noradrenergic hyperactivity which is responsible 
for the observed withdrawal syndrome is blunted by the administration of the 
alpha-2 agonist clonidine, resulting in a rapid yet tolerable detoxification 
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procedure. It should be noted that although the clonidine/naltrexone group 
experienced the greatest degree of withdrawal symptoms, their mean peak 
symptom severity score of 25.8 (± 15.7) indicates only a mild severity of 
symptoms. This is consistent with previous reports by authors examining the 
clonidine/naltrexone detoxification procedure who found that this method of 
opiate detoxification provided significant relief of withdrawal symptoms 
(Charney et af., 1986; Kleber et al., 1987; Vining et al., 1988). 
In Figures I and II, the curves representing the symptom scores of the 
buprenorphine group indicate that patients in this group tolerated the 
transition from illicit opiates to buprenorphine quite well during days 1 
through 3. There was a significant drop in mean current symptom severity 
score during this period. These results are consistent with those observed 
by Kosten and Kleber (1988), who studied methadone and heroin addicted 
patients as they were detoxified with buprenorphine over the course of thirty 
days. The symptom severity scale used in the present study was identical to 
that used by Kosten and Kleber (maximum score = 72), so valid 
comparisons between the two studies in terms of symptom severity score 
can be made. During the first three days of buprenorphine treatment, Kosten 
and Kleber found that patients who were heroin users had a mean symptom 
severity score of 18 (± 14.3). In the present study, this value is 14.7 (+ 12.2). 
This indicates that the patients in the buprenorphine groups in the present 
study and in Kosten and Kleber's study had similar low intensities of 
withdrawal symptoms during induction onto buprenorphine from heroin. 
This pattern of mild withdrawal symptoms that decline over a few days after 
transition from heroin to buprenorphine was also noted by Johnson et al. 
(1989). Bickel et al. (1988b) noted patients who were converted from heroin 
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to buprenorphine to experience mild but constant withdrawal symptoms 
during the first week of buprenorphine treatment. 
In the present study, an increase in the mean current symptom 
severity score and a significant increase in the mean peak symptom severity 
score were noted for the buprenorphine group between days 3 and 5. This 
is the period of transition from buprenorphine to naltrexone plus clonidine. 
Kosten and Kleber (1988) did not observe any increase in withdrawal 
symptoms when their patients who were maintained on buprenorphine (2 or 
4 mg./day s.l.) for thirty days were abruptly discontinued from buprenorphine 
treatment. Kosten and Kleber waited 24 hours before initiating low-dose 
naltrexone therapy (1 mg.) in these patients, with no resulting increase in 
symptoms. In the present study, patients were maintained on 3 mg./day s.l. 
of buprenorphine for three days, and then 25 mg. of naltrexone were 
administered on day 4, preceded by 0.2 mg. of clonidine (24 hours after the 
last dose of buprenorphine). A resultant rise in mean current and peak 
symptom severity scores, and a slight rise in the mean systolic blood 
pressure of the group was then observed. 
The differences in withdrawal signs and symptoms noted above 
between patients in the buprenorphine group of the present study and the 
study of Kosten and Kleber could be due to the significantly larger dose of 
naltrexone used in the present study. In a separate pilot study by Kosten et 
al. (1989), the authors did observe significant signs of opiate withdrawal 
when large doses of naloxone (32 mg.) were administered to patients who 
had been maintained on buprenorphine (3 mg./day s.l.) for one month. As 
described by Ranee (1979), the slow kinetics of the buprenorphine-opiate 
receptor interaction may be responsible for the difficulty in reversing 
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buprenorphine's effects with low doses of an opiate antagonist. Animal 
studies have confirmed that naloxone is 1/30 as potent in precipitating 
withdrawal in buprenorphine-dependent dogs than it is in precipitating 
withdrawal in morphine-dependent dogs (Martin 1979). This difficulty in 
precipitating withdrawal was also noted in human subjects maintained on 
buprenorphine by Jasinski et al. (1978). These authors failed to observe 
any signs of the opiate withdrawal syndrome after administering 4 mg. of 
naloxone to patients who were maintained on buprenorphine (8 mg./day 
s.c.) for 45 to 54 days. 
The purpose of the buprenorphine protocol in this study was to 
achieve a smooth transition from heroin to buprenorphine, and then achieve 
a relatively comfortable transition from buprenorphine to naltrexone therapy. 
As discussed above, the transition from heroin to buprenorphine was quite 
successful. The transition from buprenorphine to naltrexone therapy did 
result in an increase in withdrawal symptom scores. However, as indicated 
in Figure II, the severity of the mean peak withdrawal symptoms experienced 
by the buprenorphine group remained mild. Also, these scores for the 
buprenorphine group remained less than those observed on days 2 through 
4 in the clonidine/naltrexone group, whose patients were transferred directly 
from heroin to naltrexone (days 2-4 respectively: t=1.91, p=0.06; t=3.51, 
p<0.005; t=2.26, p<0.05). Therefore, while the clonidine/naltrexone and 
buprenorphine protocols are equally effective in achieving opiate 
detoxification, the buprenorphine protocol offers the advantage of a greater 
degree of withdrawal symptom palliation. 
Several aspects of the buprenorphine protocol make it well suited for 
use by a primary care physician. The present study has shown that 
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buprenorphine is effective as a transitional agent between illicit opiate use 
and naltrexone therapy when buprenorphine is administered for only three 
days. This allows the physician to legally prescribe this opiate for purposes 
of detoxification, as current narcotic laws prohibit physicians from 
prescribing opiates for this purpose for more than three days (The 
Comprehensive Drug Abuse Prevention and Control Act of 1970, Public Law 
91-513, Title II). Also, the present study supports previous evidence that 
buprenorphine is effective when administered sublingually (Jasinski et al., 
1989; Seow et al., 1986). The sublingual preparation allows for easy and 
painless dispension of buprenorphine to patients. 
This study has demonstrated that each of the three methods of opiate 
detoxification examined are safe for application in a primary care setting. 
Vigilant monitoring of blood pressure is required as clonidine can potentially 
cause symptomatic hypotension. However, in the present study and the 
studies reviewed herein, there has been only one report of clinically 
significant hypotension that required treatment, and that occurred in the 
setting of acute gastroenteritis (O’Connor et al., in press). The treatment 
groups that received clonidine in the present study did have statistically 
significant decreases in systolic blood pressure (Figure V), and although 
these drops in systolic blood pressure are clinically significant, there were 
no episodes of symptomatic hypotension aside from occasional postural 
lightheadedness. Furthermore, the methods of opiate detoxification outlined 
here were sufficiently successful in controlling withdrawal symptoms, and 
none of the patients displayed any violent or disruptive behaviors. Any 
agitation or restlessness that was observed was easily controlled by the 
medical staff at the clinic. Therefore, the only special adaptations that a 
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primary care physician would need to make in order to attempt opiate 
detoxification by one of the three methods presented here, aside from 
knowledge of the protocols themselves, would be the ability to monitor 
patients’ blood pressure frequently during the acute phases of detoxification, 
and the ability to supply a quiet place where the patients could rest during 
the days of greatest discomfort. Of course, the physician would also need to 
make himself or herself aware of the various relapse prevention programs 
available, and be able to refer his patients to those programs after 
successful detoxification. 
There are several major benefits of being able to conduct opiate 
detoxification in a primary care setting. First, it expands a physician’s ability 
to provide care for his or her patients, eliminating the need to refer an opiate- 
addicted patient to a detoxification center. This not only increases the 
availability of opiate detoxification, which is currently quite limited, but may 
encourage patients who would otherwise be hesitant to enroll at 
detoxification centers to seek treatment with their own private physician. By 
providing opiate detoxification services, physicians could decrease the 
staggering waiting lists that exist currently for specialized detoxification 
centers. These waiting lists only add to the frustration of addiction, and likely 
deter many otherwise willing patients from entering detoxification. By 
shifting opiate detoxification from inpatient to outpatient locations, the cost of 
detoxification is certainly decreased. By increasing availability of opiate 
detoxification and physically linking detoxification with general medical care, 
opiate addicts will be connected with the health care system. This would 
provide an opportunity for education about the medical complications of 
intravenous drug use, and could possibly have a beneficial effect on the 
. 
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transmission rate of diseases that are communicable through intravenous 
drug use. Also, many opiate addicts present to detoxification with active 
medical problems, and these could be addressed by the primary care 
physician after detoxification was complete. The effectiveness of the current 
methods of opiate detoxification outlined here has made it possible to 
conduct the treatment of opiate addiction in a primary care-based outpatient 
setting. 
The present study raises questions that remain to be answered. 
Although 75% of patients who were successfully detoxified were referred to 
relapse prevention programs, their status after referral is unknown. It would 
be quite helpful to obtain follow-up information about these patients to 
determine if the acute detoxification treatment they received had any bearing 
on successful long-term abstinence from opiates. This information would 
also aide in identifying any predictors of successful long-term opiate 
abstinence. A longer period of follow-up would also be useful to determine if 
any patients in the buprenorphine group experienced withdrawal symptoms 
several days after initiating naltrexone therapy, as the buprenorphine 
withdrawal syndrome has been observed to be mild but occasionally 
delayed and protracted (Jasinski et al., 1978; Fudala et al., 1990; Seow et 
al., 1986). The present study has confirmed the previous successes 
obtained with a clonidine/naltrexone protocol. It now may be time to 
encourage physicians to allow this protocol to move out of experimental 
situations and into general use. 
The present study has demonstrated that opiate detoxification utilizing 
clonidine/naltrexone or buprenorphine is more effective than with clomdine 
alone, and that buprenorphine ameliorates withdrawal symptoms to a 
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greater degree than does clonidine/naltrexone. Furthermore, opiate 
detoxification with clonidine, clonidine/naltrexone, and buprenorphine can 
be safely and successfully carried out in a primary care-based, outpatient 
setting. Hopefully, these methods of opiate detoxification will continue to be 
perfected in order to allow as many patients as possible the opportunity for 
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